Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
8.70
-0.64 (-6.85%)
Jul 24, 2026, 3:17 PM EDT - Market open
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $-29.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $65.50M, up 213.96% year-over-year. In the year 2025, Vir Biotechnology had annual revenue of $68.56M, down -7.61%.
Revenue (ttm)
$65.50M
Revenue Growth
+213.96%
P/S Ratio
22.56
Revenue / Employee
$178,460
Employees
367
Market Cap
1.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.56M | -5.65M | -7.61% |
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Innoviva | 420.69M |
| AnaptysBio | 232.39M |
| Xencor | 97.36M |
| Zymeworks | 81.26M |
| Septerna | 72.26M |
| Recursion Pharmaceuticals | 66.41M |
| Intellia Therapeutics | 66.09M |
VIR News
- 6 hours ago - Vir Biotechnology CFO Jason O’Byrne to depart - TheFly
- 6 hours ago - Vir Biotechnology Announces Chief Financial Officer Transition - Business Wire
- 1 day ago - Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - Business Wire
- 6 weeks ago - Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley - TheFly
- 6 weeks ago - Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - Business Wire
- 2 months ago - Vir Biotechnology Transcript: AGM 2026 - Transcripts
- 2 months ago - Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TheFly
- 2 months ago - Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire